Skip to main content

Subgroup pooled analyses

Improvement in ISS7 and UAS7 at Week 24 with DUPIXENT Across a Broad Range of CSU Patient Types (12+ Years)

in a post-hoc pooled analysis of CUPID A and CUPID C, regardless of1,2:
  • IgE levels
  • BMI
  • Angioedema

Real adult CSU patient being treated with DUPIXENT.
Individual results may vary.

Itch improvement stratified by baseline IgE in a post hoc pooled analysis

CUPID-A AND CUPID-C
(12+ YEARS)

CONSISTENT IMPROVEMENT IN ISS7 AT WEEK 24
REGARDLESS OF PATIENTS’ BASELINE IgE1,2

Reduction in both itch and hives stratified by baseline IgE in a post hoc pooled analysis

CUPID-A AND CUPID-C
(12+ YEARS)

CONSISTENT IMPROVEMENT IN UAS7 AT WEEK 24
REGARDLESS OF PATIENTS’ BASELINE IgE1,2

Itch improvement stratified by baseline BMI in a post hoc pooled analysis

CUPID-A AND CUPID-C
(12+ YEARS)

GENERALLY CONSISTENT IMPROVEMENT IN ISS7 AT WEEK 24
REGARDLESS OF PATIENTS’ BASELINE BMI2

Reduction in both itch and hives stratified by baseline BMI in a post hoc pooled analysis

CUPID-A AND CUPID-C
(12+ YEARS)

GENERALLY CONSISTENT IMPROVEMENT IN UAS7 AT WEEK 24
REGARDLESS OF PATIENTS’ BASELINE BMI2

Consistent itch improvement regardless of angioedema in a post hoc pooled analysis

CUPID-A AND CUPID-C
(12+ YEARS)

ISS7 IMPROVEMENT AT WEEK 24 REGARDLESS OF ANGIOEDEMA2

Consistent disease activity improvement regardless of angioedema in a post hoc pooled analysis

CUPID-A AND CUPID-C
(12+ YEARS)

UAS7 IMPROVEMENT AT WEEK 24 REGARDLESS OF ANGIOEDEMA2

See which patients with CSU may be appropriate for DUPIXENT

IDENTIFY PATIENTS

BMI, body mass index; CSU, chronic spontaneous urticaria; ISS7, itch severity score over 7 days; LSM, least squares mean; UAS7, urticaria activity score over 7 days.